The inhibition of proteasome activity with inhibitors such as bortezomib, epoxomicin, and PR-957 (ONX-0914) significantly attenuates hypertension, cardiac remodelling, heart failure, atrial fibrillation and retinopathy after angiotensin II infusion or pressure overload. This evidence concerns the gene AGT and Hypertension.